QIAGEN N.V. |
Market Closed -
Other stock markets
|
Pre-market 07:58:21 am | |||
| 43.42 USD | -0.02% |
|
43.26 | -0.37% |
| Dec. 05 | Qiagen Reports Over 1,000 Placements of EZ2 Connect Instrument Globally | MT |
| Dec. 05 | Qiagen N.V. Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference, Dec-05-2024 10:50 AM |
Summary: Qiagen N.V.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Highlights: Qiagen N.V.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- The company is in a robust financial situation considering its net cash and margin position.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses: Qiagen N.V.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 58.7 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 5 times the sales for the current fiscal year, the company turns out to be overvalued.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings Chart: Qiagen N.V.
Source: Surperformance
ESG chart: Qiagen N.V.
Source: Refinitiv
| Composite Fundamentals | Composite Valuation | Composite Momentum | Capi. ($) | ||
|---|---|---|---|---|---|
| 9.65B | |||||
| 43B | |||||
| 36.78B | |||||
| 26.11B | |||||
| 17.95B | |||||
| - | 17.1B | ||||
| 16.5B | |||||
| 11.84B | |||||
| 10.87B | |||||
| 9.81B | |||||
| Average | 19.96B | ||||
| Weighted average by Cap. |
Investor Rating
Trading Rating
ESG Refinitiv
A
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- QGEN Stock
- Ratings Qiagen N.V.